BSG and COVID-19: In contrast, CD147 has been proposed as a SARS-CoV-2 receptor since the early months of the COVID-19 pandemic (13, 68), and treatment with the humanized CD147 mAb meplazumab was shown to accelerate the recovery of hospitalized COVID-19 patients in a small Phase II clinical trial (69).